retatrutide clinical trial phase Trials: 28.7% Weight Loss (TRIUMPH-4) Retatrutide for weight loss: Study

As a result, it induces satiety and regulates food intake ( Apart from its metabolic effects, GLP-1 exerts a wide range of physiological actions

Competing interests The authors declare that there is no conflict of interest

They follow a predictable pattern across the trials, and slow dose increases are the most reliable way to reduce them

Tirzepatide is not indicated for type 1 diabetes and should not be used in combination with other GLP-1 receptor agonists or weight management medications

Managing Reactions If injection site reactions occur: Ice the area for 10 minutes before injection to numb it Take an antihistamine (diphenhydramine 25mg) 30 minutes beforehand Apply hydrocortisone cream after injection to reduce itching Switch to a different injection site area Long-Term Safety Considerations Because Retatrutide is still in Phase 3 clinical trials, our longest safety data comes from the 48-week Phase 2 study

doi: 10.1073/PNAS.0806720106 30 FerreiraJPSaraivaFSharmaAVasques-NvoaFAnglico-GonalvesALeiteARet al